simplyStocks
Explore all companies →
McKesson
MCK · NYSEHealthcare Distribution
The economic chain
Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
ProductsMedicines, therapies, dev…Payers &distributionWholesalers, PBMs, health…Providers &patientsHospitals, surgeons, pati…PFEPfizerLLYEli LillyRXGeneric & specialty drugmakersMCKMcKessonNAPNorth American PharmaceuticalCMMCoverMyMeds platformRxTSPrescription Technology SolutionsONCOncology & MultispecialtyMSMedical-Surgical SolutionsCVSCVS HealthWMTWalmartRX+Pharmacies & retail chainsHOSPHospitals, clinics & oncologistsPTPatients
Company details
Market cap
$93B
P/E ratio
21×
Div yield
0.4%
EPS (FY26)
$38.53
Net income
$4.8B
Rev. growth
+12%
Revenue
$403B
Free cash flow
$10B
In plain English
McKesson is the plumbing of American medicine: a ~$403B-revenue wholesaler that buys drugs in bulk from manufacturers and ships them to almost every US pharmacy, hospital and clinic — with CVS, Walmart and big buying groups as anchor customers. On top of that low-margin river of pills it is bolting a higher-margin specialty business: oncology and ophthalmology practice networks (Florida Cancer Specialists, PRISM Vision) and prescription-access software (CoverMyMeds), while planning to spin off its Medical-Surgical arm.
In simple terms
What McKesson really sells
McKesson is the plumbing of American medicine: a ~$403B-revenue wholesaler that buys drugs in bulk from manufacturers and ships them to almost every US pharmacy, hospital and clinic — with CVS, Walmart and big buying groups as anchor customers. On top of that low-margin river of pills it is bolting a higher-margin specialty business: oncology and ophthalmology practice networks (Florida Cancer Specialists, PRISM Vision) and prescription-access software (CoverMyMeds), while planning to spin off its Medical-Surgical arm.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.
Risk read
Moderate
SteadierMore speculative
Why this rating?